Introduction: Renal involvement affects about 50% of SLE patients accounting for significant morbidity and mortality in these patients. The adipokine ''visfatin'' acting as a growth factor for B-lymphocyte-precursors, exerts several proinflammatory functions. It was demonstrated as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD) thus could be a factor linking inflammation in SLE and kidney disease.
patients into active versus inactive and LN versus non-LN respectively. Renal biopsies were taken from LN subgroup and were classified according to the modified WHO classification.
Results: A significantly higher serum visfatin level was found on comparing SLE patients (mean 109 ± 180 ng/ml, median18) with controls (mean 9.4 ± 11 ng/ml, median2.5) with statistically highly significant difference (z = 5.2, P < 0.001). Also there was a statistically significant difference as regards serum visfatin level between active SLE patients (mean 173 ± 111 ng/ml, median 14) and inactive patients (mean 139 ± 88 ng/ml, median 5) (z = 2.1, P < 0.05) as well as between patients with LN (mean 226 ± 180 ng/ml, median18) and patients with no LN (mean 101 ± 140 ng/ml, median 8(2-229)) (z = 2.1, P < 0.05). Visfatin had a highly significant positive correlation with disease duration (r = 0.48, P < 0.001), SLEDAI (r = 0.62, P < 0.001) as well as ESR, CRP and, renal score (r = 0.45, 0.35, and 0.65, respectively) while inverse correlation with estimated GFR (r = À0.614) and C3 and C4 titre (r = À0.26, r = À0. 35 , respectively) was recorded. Visfatin showed high sensitivity in detecting active SLE and LN 83% and 85%, respectively.
Conclusion: Serum visfatin is strongly associated with LN in SLE patients and is a promising biomarker for prediction of renal involvement in these patients. It reflects SLE activity specially LN activity namely renal score and GFR decline. Further prospective studies are required to confirm visfatin as a destructive mediator of predictive and prognostic value in active lupus nephritis.
Introduction
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem disease mainly affecting women of childbearing age. It is characterized by a very large spectrum of clinical manifestations accompanied by prototypic abnormalities of the immune system. While recent advances in therapeutic approaches have taken place, SLE still has a profound impact on the quality of life and life expectancy of affected persons [1] .
Kidney involvement is a major concern in SLE, affecting 50% of patients and accounting for significant morbidity and mortality. Its clinical presentations are highly variable, ranging from mild asymptomatic proteinuria and/or hematuria to rapidly progressive uremia. Early diagnosis and prompt treatment may dramatically modify the course of renal disease and improve the long term survival [2] .
The term 'adipokine' is generally applied to biologically active substances found in the adipocytes of White Adipose Tissue (WAT); however, these factors are synthesized at other sites and participate in functions unrelated to those within WAT [3] . There has been much effort recently to define the role of adipokines in the interaction between adipose tissue, inflammation and immunity [4] .
Leptin, adiponectin and resistin are the most extensively studied adipokines. Leptin may promote inflammation by inducing Th1 phenotype development, where as adiponectin may combat inflammation by reducing the production of pro-inflammatory cytokines. Resistin belongs to a family of proteins found in foci of inflammation, where they contribute to the inflammatory response. All three adipokines have been detected in synovial fluid from joints affected with the inflammatory disease rheumatoid arthritis (RA) or the degenerative disease osteoarthritis (OA) [5] .
One of the most recently identified adipokines is visfatin [6] , originally discovered in liver, skeletal muscle and bone marrow as a growth factor for B lymphocyte precursors (whence its alternative name, pre-B-colony enhancing factor, or PBEF). Interestingly, it has also been implicated to be produced by immune cells (e.g. neutrophils and macrophages) [7] . Visfatin synthesis is regulated by several factors, including glucocorticoids, TNF, IL-6 and growth hormone and it has been recently demonstrated to exert several pro-inflammatory functions [8] .
Visfatin has insulin-mimetic effects and exists in high levels in foam cell macrophages within unstable atherosclerotic regions that play a role in plaque destabilization [9] . Plasma visfatin concentration is related to endothelial dysfunction in type 2 diabetic patients [10] . Also, patients with inflammatory bowel disease (IBD) were found to have elevated circulating visfatin levels and increased levels of visfatin mRNA in their intestinal epithelium [11] . Furthermore, visfatin is also reported as nicotinamide phosphoribosyltransferase (Nampt), which is an essential enzyme in the nicotinamide adenine dinucleotide (NAD) biosynthetic pathway [12] .
In addition, circulating visfatin is higher in patients with RA than in healthy controls. Visfatin expression is detected in synovial fibroblasts in RA patients and visfatin itself activates the nuclear factor-kappa B (NF-kB) and related various proinflammatory cytokines in cultured synovial fibroblasts [13] . More recently, Gomez et al., 2011 studied serum and synovial fluid visfatin in RA patients and found them significantly higher in all RA patients and patients with active disease compared to the control group and Neveen patients in remission. Serum Visfatin was positively correlated with disease activity in RA [14] . Moreover, OA patients had higher synovial fluid (SF) visfatin concentration compared to control that increases with OA severity. SF visfatin positively correlated with degradation biomarker of collagen II and aggrecan suggesting its involvement in cartilage matrix degradation [15] .
Recently, visfatin, was shown to be associated with soluble vascular cell adhesion molecule-1 (sVCAM-1) and act as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD) and could be a factor linking inflammation and kidney disease [16] . Collectively, these results suggest a new physiological role of visfatin in organ injury and could be a factor linking inflammation and kidney disease.
The aim of this study was to assess the level of serum visfatin in SLE patients and to detect any possible correlation to disease activity and lupus nephritis in these patients.
Patients and methods
The present study is a cross sectional one that included 40 patients with SLE fulfilling the updated American College of Rheumatology (ACR) criteria [17] . They were selected the Rheumatology and Nephrology in and out-patient departments in Ain Shams University Hospitals. Forty age and sex matched healthy subjects were also included in the study and served as control group. All the patients were on steroids and cytotoxic drugs. Oral consent was obtained from all patients and controls after a full explanation of the study.
Exclusion criteria
Patients with diabetes mellitus, malignancies, overlap syndrome, metabolic syndrome, liver disease, IBD or on hemodialysis were excluded from the study. -Measurement of serum visfatin was done by enzyme linked immunosorbent assay (ELISA) for quantitative determination of visfatin in human serum, detection range (1.56-100 ng/ml). The intra-assay coefficient of variations was 5.6. Plasma was stored frozen at -80°C until measurement.
Clinical

Renal biopsy
Renal biopsies were taken from the patients with LN. Serum samples had to be taken at the time of the renal biopsy ± 7days and were stored at À80°C until further use. All biopsies were classified according to the modified WHO classification into six classes [19, 20] normal, mesangial, focal segmental, diffuse proliferative, membranous or advanced sclerosis. The classification was done on the basis of the most prominent lesion. The statistical analysis was performed by IBM SPSS statistics (V. 19.0, IBM Corp., USA, 2010) used for data analysis. Data were expressed as Mean ± SD for quantitative measures.
The following tests were done:
1. Comparison of two independent mean groups for parametric data using Student t test. 2. Comparison between two independent groups for nonparametric data using Wilcoxon Rank Sum test. 3. Ranked Spearman correlation test to study the possible association between each two variables among each group. 
Results
Clinical and laboratory data of SLE patients
Comparison between active and inactive SLE patients
By using SLEDAI for assessment of disease activity, there were 19 active patients (47.5%) with their SLEDAI > 8. While the other 21 patients (52.5%) were inactive (SLEDAI < 8).
The active group had a higher ESR and CRP and a lower C3 compared to the inactive group. While there was statistically non significant difference between both groups as regards age, disease duration, renal score and other laboratory data ( Table 3 ). The Visfatin level was significantly higher among the active (mean 173 ± 111, median 14) compared to the inactive group (mean 139 ± 88, median 5) (z 2.1, P < 0.05) using Mann Whitney Willcoxon U test (Table 3 ).
Comparison between SLE patients with and without lupus nephritis
Assessment of lupus nephritis by renal SLEDAI, revealed that 22 patients (55%) had lupus nephritis (renal SLEDAI score>8) while 18 patients (45%) had no lupus nephritis (renal SLEDAI score < 8). There was a statistically significant difference between both groups as regards SLEDAI and C4 level while there was statistically non significant difference between both groups as regards age, disease duration and other laboratory data (Table 4 ). Comparison between SLE patients with nephritis and patients with no nephritis as regards serum visfatin showed that visfatin level was significantly higher among the LN compared to the non-lupus nephritis group (mean 226 ± 180, median 18(6.2-112) versus (mean 140 ± 101, median 8(2-229)) (P < 0.05), (Table 5) .
Low C3 and normal C4 concentrations were found in only 1 patient (5%). Normal C3 and low C4 concentrations (74%) were commonest in lupus nephritis group. Two patients (11%) with lupus nephritis showed low C3 in the presence of low C4 concentration. There were 10% with normal C3 and C4.
Correlation between visfatin levels and studied variables in SLE
Renal biopsies were taken from the patients with LN (n = 22). The majority of patients had II, III or IV lupus nephritis (LN). All patients had a positive staining for glomerular C3. Three of the 22 patients had class V (membranous) lupus nephritis corresponding to a class Va nephritis according to the modified 1982 WHO classification according to Weening et al. in 2004 [19,20] . The other LN patients (n = 19) were classes II-IV and considered as active (proliferative) lupus nephritis.
Assessment of visfatin was done at the time of renal biopsy and it correlated significantly with the grades of renal biopsy (0.32, P < 0.05) (Fig. 1) . Figure 1 Correlation between serum visfatin and renal biopsy class (according to WHO classification grading).
Correlation studies (Table 6 ) between visfatin level and clinical data of SLE patients showed a statistically highly significant correlation (P < 0.001) between the visfatin and duration of disease (r 0.48), SLEDAI (r 0.62) and renal score (r 0.65) ( fig.  2 and 3 ). As regards laboratory data, a positive highly significant correlation between the visfatin level and ESR and CRP was found (r 0.45 and 0.35, respectively). Also a significant inverse correlation existed between visfatin and estimated GFR (r = À0.614, P < 0.001), C3 as well as C4 titre (r = À0.614, À0.26, À0.35, respectively). On the other hand non-significant correlations between visfatin and other demographic and laboratory parameters were recorded (Table 6 ).
Validity of visfatin in prediction of SLE activity and lupus nephritis
For the detection of active SLE, the visfatin assay showed a sensitivity of (83%) and negative predictive value (85%). Specificity and positive predictive value were 60% and 59%, respectively. The corresponding receiver operating characteristic (ROC) curve is demonstrated in Fig. 4a (area under the curve = 0.74, 74%, accuracy 62%) ( Table 7 , Fig. 4a ).
For the detection of active lupus nephritis, the visfatin assay showed a sensitivity of (85%) and negative predictive value (89%). Specificity and positive predictive value were 60% and 67%, respectively. The corresponding receiver operating characteristic (ROC) curve is demonstrated in Fig. 4b (area under the curve = 0.77, 77%, accuracy 65%) ( Table 7 , Fig. 4b ).
Discussion
SLE is a prototype of an autoimmune syndrome that is characterized by various organ manifestations. Lupus nephritis is one of the most serious manifestations of SLE. This organ manifestation has traditionally been characterized by the World Health Organization classification criteria, which focuses on histological parameters [19, 20] . Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is an adipocytokine that recently generated much interest [11] ; however, its role in chronic kidney disease (CKD) remains to be clarified. This study aimed to assess visfatin in SLE patients and its correlation with disease activity and lupus nephritis in these patients.
In this study SLE patients exhibited higher visfatin level compared with the controls. This is in agreement with Chung et al. study in 2009 [21] who measured the concentrations of different adipocytokines as resistin, leptin, adiponectin and visfatin in 109 patients with SLE and 78 control subjects. They recorded that serum visfatin was higher in patients with SLE than in controls. Also, De Sanctis et al., [22] in 2009 reported the same findings in their studied SLE patients. They all concluded that visfatin is involved in the inflammation and metabolic imbalance of patients with SLE. On the other hand, Ozgen et al. [23] studied serum visfatin level and its association with common carotid intima-media thickness, which is a predictor of atherosclerosis, in patients with RA, SLE, systemic sclerosis (SSc), and Behc¸et's disease (BD). They stated it was higher in the RA and active BD groups, but not in the SLE and SSc groups.
Other investigators [4, 5, 24] have reported the elevated visfatin level in rheumatic diseases as rheumatoid arthritis and osteoarthritis. In 2011, Gomez et al. [14] and Duan et al. [15] published important studies highlighting the importance of Visfatin in RA and OA, respectively relating it to disease activity and severity. Other adipokine, adiponectin, was higher in patients with various autoimmune diseases including SLE [25] . The physiological role or relevance of adipokines, namely visfatin, in these inflammatory diseases might involve modulation of the inflammatory or immune response as visfatin induces chemotaxis and increases the production of IL-1, TNF, IL-6 and costimulatory molecules by CD14 + monocytes. This increases their ability to induce alloproliferative responses [26] . Another explanation is that elevated visfatin level might be also up-regulated during inflammation and in response to pro-inflammatory cytokines or the increased levels could simply be an epiphenomenon [26] .
Hence, studies have indicated that visfatin activates human leukocytes and stimulates the production of pro-inflammatory cytokines [8] More recently, Evans et al. [27] showed that Visfatin stimulated matrix metalloproteinases production, synovial inflammation and chemokine-directed leukocyte infiltration. In this study the positive correlation between visfatin and CRP supports the role of visfatin as an inflammatory mediator. This is also in accordance with Oki study in 2007 [28] who reported also this positive correlation. They concluded that the elevated concentrations of visfatin could reflect systemic inflammation. This is also in accordance with Bessa et al. [29] who found serum visfatin, VCAM-1, CRP were significantly elevated in CKD patients as compared to controls and that Visfatin correlated positively with VCAM-1 and CRP.
The finding that PBEF/visfatin is preferentially expressed and secreted by visceral adipose has mainly, though not universally, been upheld in many studies denoting visfatin levels are more pronounced in obese humans. One hypothesis is that the hypoxia that occurs as fat cells increase in size can induce visfatin expression [30] . Another hypothesis notes that macrophages are more prevalent in obese adipose tissue, especially surrounding apoptotic adipocytes. These macrophages join adipocytes in producing visfatin [31] . Regardless of how a visfatin differential is created, once it exists it has the ability to promote adipogenesis [6] .
However, this study did not find a statistical correlation between visfatin levels with the BMI may be because of the small number of SLE patients with their BMI within normal range; (23.7 ± 3 kg/m 2 ).
Data from Yilmaz and his colleagues study in 2008 [16] support our observation of the inverse correlation between circulating visfatin level and GFR. They studied 406 patients with different stages of CKD while 80 healthy volunteers served as matched controls. Visfatin levels were strongly correlated with the decrease in GFR. They explained these results: that recently, visfatin, was shown to be associated with sVCAM-1 and acts as a marker of ED in CKD and could be a factor linking inflammation and kidney disease [16, 32, 33] . This is also in accordance with the study by Mu et al. [34] who described that CKD patients with higher visfatin levels were associated with lower GFR and impaired endothelial function. We found a highly significant positive correlation between the mean values of visfatin and SLEDAI as well as a significantly higher visfatin among the active SLE group compared to the inactive group. This is in accordance with the study of Stofkova who had mentioned that visfatin is up-regulated during inflammation and in response to pro-inflammatory cytokines. He had also added that visfatin itself can contribute to the inflammatory processes by triggering cytokine production and NF-kappa B activation [26] . The specific relationship between visfatin and inflammation in SLE as well as disease activity has not been enough elaborated in further studies.
In another study by Yilmaz et al., also in 2008 [35] researchers analyzed circulating visfatin levels in diabetic nephropathy patients. They found that with increasing visfatin, patients proved to have higher degree of proteinuria and suggested it is an important predictor of endothelial dysfunction in early diabetic nephropathy. In this study, a positive but non-significant correlation existed between visfatin and proteinuria. However to our knowledge, there are only few investigators who studied this correlation so more studies with larger number of patients are needed to clarify this correlation.
In this study the LN group had higher visfatin level compared to patients with no LN. Also a highly significant positive correlation between visfatin and renal score was recorded. Visfatin showed similar specificity for detection of active SLE and lupus nephritis, but had more sensitivity, negative and positive predictive values and more accuracy for detection of LN than SLE activity. This was in accordance with a study by Kang et al. [36] who stated that visfatin is produced by renal cells and has an important paracrine role in the pathogenesis of nephropathy and was significantly higher in presence of nephritis.
It is now clear that adipokines have multiple important roles in the body, and the increasing research effort in this area is gradually revealing the intricate adipokine-mediated interplay between adipose tissue, metabolic disorders and inflammatory autoimmune disorders. New insight into the role of adipokines makes them attractive targets for novel therapeutic strategies in chronic inflammatory diseases.
In conclusion, serum visfatin is strongly associated with LN in SLE patients and is a promising biomarker for prediction of renal involvement in these patients. It reflects SLE activity and LN namely renal score rise and GFR, C3 and C4 decline. Further prospective studies are required to confirm visfatin as a destructive mediator and prognostic factor in active lupus nephritis.
